Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Chief Medical Officer | March 24, 2023 | March 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date March 24, 2023 · Filed March 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 730,345 |
Reported balance
After 2023-03-24 transaction · row 1
1 source rowRow 1 · 2023-03-24 · Grant · Acquired 209,803 · Balance 730,345 F1: Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.71 · Expires 2031-09-12 | Direct | 0 |
Reported balance
After 2023-03-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-24 · Disposition to issuer · Disposed 157,257 · Balance 0 F2: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3: These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.71 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-03-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-24 · Disposition to issuer · Disposed 17,517 · Balance 0 F2: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2031-09-12 | Direct | 157,257 |
Reported balance
After 2023-03-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-24 · Grant · Acquired 157,257 · Balance 157,257 F2: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3: These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2031-09-14 | Direct | 17,517 |
Reported balance
After 2023-03-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-24 · Grant · Acquired 17,517 · Balance 17,517 F2: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
F3: These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F4: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2023 Filed Mar 28, 2023 16:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 17,517 | Not disclosed Strike: $2.21 | Not disclosed |
DisclosureSEC source: 0001209191-23-021412 · doc4.xml · derivative · entry 5 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,517 Underlying: Common Stock · 17,517 shares Expires 2031-09-14 F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 157,257 | Not disclosed Strike: $2.21 | Not disclosed |
DisclosureSEC source: 0001209191-23-021412 · doc4.xml · derivative · entry 4 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,257 Underlying: Common Stock · 157,257 shares Expires 2031-09-12 F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | Disposition to issuerStock Option (Right to buy) · Derivative | 17,517 | Not disclosed Strike: $8.71 | Not disclosed |
DisclosureSEC source: 0001209191-23-021412 · doc4.xml · derivative · entry 3 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,517 shares Expires 2031-09-14 F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | Disposition to issuerStock Option (Right to buy) · Derivative | 157,257 | Not disclosed Strike: $8.71 | Not disclosed |
DisclosureSEC source: 0001209191-23-021412 · doc4.xml · derivative · entry 2 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,257 shares Expires 2031-09-12 F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:45 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 209,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021412 · doc4.xml · nonDerivative · entry 1 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730,345 F1 · shares: Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 19:38 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 53,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000067 · doc1.xml · nonDerivative · entry 1 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,542 F1 · shares: Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 19:58 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 115,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008614 · doc1.xml · nonDerivative · entry 1 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,611 F1 · shares: Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date. F2 · shares: The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 53,931 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:16 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 306,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-012918 · form4.xml · nonDerivative · entry 1 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,680 F1 · shares: Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 19:47 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to buy) · Derivative | 436,929 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034424 · form4.xml · derivative · entry 2 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,929 Underlying: Common Stock · 436,929 shares Expires 2031-10-07 F2 · derivative.exercise_date: These stock options vest 25% on the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 19:47 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-034424 · form4.xml · nonDerivative · entry 1 Feingold Jay · CIK 0001885838 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 F1 · shares: Represents shares of restricted stock that vest 25% of the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.